



REVA to Present at J.P. Morgan Healthcare Conference

Sydney, Australia and San Diego, California (Tuesday, 10 January 2017 AEDT) – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) is pleased to announce that its Chief Executive Officer, Ms. Reggie Groves, is scheduled to present at the 35th Annual J.P. Morgan Healthcare Conference. Ms. Groves’ presentation will take place at 11:00 a.m. US PST on Thursday, January 12, 2017. The conference is being held January 9th through 13th at The Westin St. Francis Hotel in San Francisco, California.

The presentation materials delivered at the conference will be available in the Investor Relations section of REVA’s website at www.revamedical.com the day of the presentation.

About REVA

REVA is a clinical stage medical device company located in San Diego, California, USA, that is working to commercialize its proprietary bioresorbable scaffolds, as an alternative to metal stents, to treat coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, then disappear (or “resorb”) from the body over a period of time. This resorption allows the return of natural movement and function of the artery, a result not attainable with permanent metal stents. The Company’s *Fantom*[®] scaffold has been designed to offer an ideal balance of thinness and strength, with distinct ease-of-use features including complete scaffold visibility under x-ray, expansion with one continuous inflation, and no procedural time limitations. REVA will require regulatory approval before it can commercialize *Fantom* or any other product.

**United States
Investor & Media Enquiries:**
REVA Medical, Inc.
Cheryl Liberatore
Director, Communications
+1 858-966-3045

**Australia
Investor Enquiries:**
Inteq Limited
Kim Jacobs
+61 438 217 279
Andrew Cohen
+61 408 333 452

**Australia
Media Enquiries:**
Buchan Consulting
Rebecca Wilson
+61 3 9866 4722